Refine your results

to


Search

Reduced-dose IMRT appropriate for induction chemotherapy responders with HPV-associated oropharyngeal cancer

Show Citation

March 7, 2017

AUTHORS:

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

PURPOSE:

Human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) is treatment-responsive. Definitive chemoradiation results in high cure rates but causes long-term toxicity and may represent overtreatment of some patients. This phase II trial evaluated whether complete clinical response (cCR) to induction chemotherapy (IC) could select patients with HPV–associated OPSCC for reduced radiation dose as a means of sparing late sequelae. ...

Advertisement
Advertisement